Olaparib monotherapy for BRCA-mutated platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer

Olaparib is a medicinal product currently in development for the treatment of Breast Cancer Gene (BRCA)-mutated relapsed ovarian, fallopian tube or primary peritoneal cancer in patients who have received at least 2 prior platinum treatments and have progressed at least 6 months after their last platinum treatment. Ovarian cancer includes a group of tumours that arise from diverse types of tissue contained in the ovary and can often spread from the ovary to any surface within the abdominal cavity including the fallopian tubes and peritoneal cavity.
Olaparib is given by mouth (tablets) and belongs to a group of drugs called poly (ADP-ribose) polymerase (PARP) enzyme inhibitors which act by preventing DNA damage repair in cancer cells, promoting cell death. Using olaparib may improve outcomes and reduce side effects in patients with relapsed ovarian cancer who have received prior platinum therapy.